Piramal Pharma (NSE:PPLPHARMA) Total Current Assets : ₹57,970 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Piramal Pharma's total current assets for the quarter that ended in Mar. 2025 was ₹57,970 Mil.

Piramal Pharma Total Current Assets Historical Data

The historical data trend for Piramal Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Total Current Assets Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Total Current Assets

17,675.00

40,672.20

48,354.80

54,644.70

57,969.90

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial											54,644.70	-	53,816.60	-	57,969.90

Piramal Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Piramal Pharma's Total Current Assets for the fiscal year that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5766.1	+	23495.2	+	23127	+	5581.6
	=	57,970

Piramal Pharma's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5766.1	+	23495.2	+	23127	+	5581.6
	=	57,970

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Piramal Pharma (NSE:PPLPHARMA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Piramal Pharma's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5766.1	-	75521.2	+	0.75 * 23495.2	+	0.5 * 23127
=	-40,570

Piramal Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Total Current Assets

Traded in Other Exchanges

543635:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramalpharma.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines